Cocrystal Pharma Q3 loss narrows

Cocrystal Pharma

14/11/2025 13:08

Overview

Cocrystal Pharma Q3 net loss decreases to $2 mln from $4.9 mln yr/yr

Company received FDA clearance for CDI-988 Phase 1b norovirus study starting Q1 2026

Company granted NIH SBIR award to advance influenza A/B replication inhibitor program

Outlook

Company to start Phase 1b norovirus study in Q1 2026

Company received NIH SBIR award for influenza A/B program

Result Drivers

Research and development (R&D) expenses for the third quarter of 2025 were $954,000, compared with $3.2 million for the third quarter of 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$2.05 mln
Q3 Basic EPS
-$0.19
Q3 Operating Expenses
$2.09 mln
Q3 Operating Income
-$2.09 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cocrystal Pharma Inc is $8.00, about 87.1% above its November 13 closing price of $1.03

Press Release: ID:nGNX14KPYm

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)